FDA Grants Accelerated Approval to Dordaviprone in Diffuse Midline Glioma
Written by
Cancer Network
Published
0
comments
0
min
Supporting data for the accelerated approval of dordaviprone come from 5 open-label trials in H3 K27M-mutant diffuse midline glioma.